allantoin has been researched along with MS (Multiple Sclerosis) in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Yeo, T | 1 |
| Bayuangga, H | 1 |
| Augusto-Oliveira, M | 1 |
| Sealey, M | 1 |
| Claridge, TDW | 1 |
| Tanner, R | 1 |
| Leppert, D | 1 |
| Palace, J | 1 |
| Kuhle, J | 1 |
| Probert, F | 1 |
| Anthony, DC | 1 |
| Becker, BF | 2 |
| Kastenbauer, S | 2 |
| Ködel, U | 1 |
| Kiesl, D | 1 |
| Pfister, HW | 1 |
| Kieseier, BC | 1 |
3 other studies available for allantoin and MS (Multiple Sclerosis)
| Article | Year |
|---|---|
Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model.
Topics: Allantoin; Animals; Biomarkers; Cytidine; Disease Models, Animal; Glucose; Glutamine; Humans; Interm | 2022 |
Urate oxidation in CSF and blood of patients with inflammatory disorders of the nervous system.
Topics: Allantoin; Blood-Brain Barrier; Brain; Central Nervous System Diseases; Guillain-Barre Syndrome; Hum | 2004 |
No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis.
Topics: Adult; Allantoin; Female; Humans; Male; Middle Aged; Multiple Sclerosis; Oxidative Stress; Uric Acid | 2005 |